• Arrowhead Pharmaceuticals, Inc. reported its third-quarter 2026 results, with sales rising to US$75.25 million from US$27.77 million a year earlier, while net loss widened to US$194.28 million and loss per share increased to US$1.36 from US$1.26.
• Over the first nine months of 2026, Arrowhead shifted from net income of US$22.12 million a year ago to a net loss of US$296.21 million despite generating more than US$400 million in sales, highlighting how rising expenses and reduced collaboration revenue are weighing on profitability.
• We’ll now examine how this combination of higher quarterly sales but deeper losses shapes Arrowhead’s existing investment narrative and risk profile.

Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Arrowhead Pharmaceuticals Investment Narrative Recap

To own Arrowhead, you need to believe its RNAi platform and late stage cardiometabolic programs can eventually offset today’s sizeable losses and heavy reliance on partner revenue. The latest quarter’s higher sales but deeper net loss sharpen near term focus on execution around upcoming late stage data and regulatory milestones, while reinforcing that rising expenses and reduced collaboration income remain the most immediate financial risk.

Against this backdrop, recent progress around REDEMPLO (plozasiran), including positive European regulatory steps earlier in 2026, looks especially relevant. As Arrowhead reports widening losses despite more than US$400 million in year to date sales, the timing and quality of plozasiran’s commercial rollout and further approvals take on added importance as a potential counterweight to growing R&D and SG&A spending.

Yet behind the strong science, there is a growing concern investors should be aware of around how long Arrowhead’s cash can support...

Arrowhead Pharmaceuticals’ narrative projects $704.7 million revenue and $133.3 million earnings by 2029.

Uncover how Arrowhead Pharmaceuticals' forecasts yield a $89.08 fair value, in line with its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were assuming Arrowhead’s revenue might fall about 15 percent a year to around US$379 million by 2029, so compared with the current swing back to sizable losses, you can see how much more pessimistic their story is about partner dependence and reimbursement risk, and why this latest quarter could prompt you to revisit which version of Arrowhead’s future you find more convincing.

Explore 3 other fair value estimates on Arrowhead Pharmaceuticals - why the stock might be worth as much as 96% more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Arrowhead Pharmaceuticals research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Arrowhead Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Arrowhead Pharmaceuticals' overall financial health at a glance.

Want Some Alternatives?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.